BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 32414851)

  • 1. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
    Singh Mali R; Zhang Q; DeFilippis RA; Cavazos A; Kuruvilla VM; Raman J; Mody V; Choo EF; Dail M; Shah NP; Konopleva M; Sampath D; Lasater EA
    Haematologica; 2021 Apr; 106(4):1034-1046. PubMed ID: 32414851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
    Zhu R; Li L; Nguyen B; Seo J; Wu M; Seale T; Levis M; Duffield A; Hu Y; Small D
    Signal Transduct Target Ther; 2021 May; 6(1):186. PubMed ID: 34024909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia.
    Tan Y; Xin L; Wang Q; Xu R; Tong X; Chen G; Ma L; Yang F; Jiang H; Zhang N; Wu J; Li X; Guo X; Wang C; Zhou H; Zhou F
    Cancer Lett; 2024 Jun; 592():216933. PubMed ID: 38705564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 6. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib
    Dumas PY; Naudin C; Martin-Lannerée S; Izac B; Casetti L; Mansier O; Rousseau B; Artus A; Dufossée M; Giese A; Dubus P; Pigneux A; Praloran V; Bidet A; Villacreces A; Guitart A; Milpied N; Kosmider O; Vigon I; Desplat V; Dusanter-Fourt I; Pasquet JM
    Haematologica; 2019 Oct; 104(10):2017-2027. PubMed ID: 30923103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill
    Post SM; Ma H; Malaney P; Zhang X; Aitken MJL; Mak PY; Ruvolo VR; Yasuhiro T; Kozaki R; Chan LE; Ostermann LB; Konopleva M; Carter BZ; DiNardo C; Andreeff MD; Khoury JD; Ruvolo PP
    Haematologica; 2022 Jun; 107(6):1311-1322. PubMed ID: 34732043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
    Cortes JE; Kantarjian H; Foran JM; Ghirdaladze D; Zodelava M; Borthakur G; Gammon G; Trone D; Armstrong RC; James J; Levis M
    J Clin Oncol; 2013 Oct; 31(29):3681-7. PubMed ID: 24002496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
    Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.
    Darici S; Jørgensen HG; Huang X; Serafin V; Antolini L; Barozzi P; Luppi M; Forghieri F; Marmiroli S; Zavatti M
    Adv Biol Regul; 2023 Aug; 89():100974. PubMed ID: 37245251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
    Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.
    Moore AS; Faisal A; Mak GWY; Miraki-Moud F; Bavetsias V; Valenti M; Box G; Hallsworth A; de Haven Brandon A; Xavier CPR; Stronge R; Pearson ADJ; Blagg J; Raynaud FI; Chopra R; Eccles SA; Taussig DC; Linardopoulos S
    Blood Adv; 2020 Apr; 4(7):1478-1491. PubMed ID: 32282883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.
    Takahashi T; Usuki K; Matsue K; Ohno H; Sakura T; Imanaka R; Murakami M; Ohwada S; Takagi T; Sakajiri S
    Int J Hematol; 2019 Dec; 110(6):665-674. PubMed ID: 31473943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
    Wang X; Mak PY; Mu H; Tao W; Rao A; Visweswaran R; Ruvolo V; Pachter JA; Weaver DT; Andreeff M; Xu B; Carter BZ
    Mol Cancer Ther; 2020 Aug; 19(8):1636-1648. PubMed ID: 32404407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
    Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
    Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
    Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quizartinib (AC220): a promising option for acute myeloid leukemia.
    Zhou F; Ge Z; Chen B
    Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
    Ma HS; Greenblatt SM; Shirley CM; Duffield AS; Bruner JK; Li L; Nguyen B; Jung E; Aplan PD; Ghiaur G; Jones RJ; Small D
    Blood; 2016 Jun; 127(23):2867-78. PubMed ID: 27103744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.